drugset / Trial / NCT00699972

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972

Phase 3 Completed 390 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, efficacy and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.

Timeline

Start
2008-04-30
Primary completion
2010-10-19
Completion
2010-10-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 8 mg
Subject Perampanel Small molecule 12 mg

Indications